<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Interv Aging</journal-id>
      <journal-id journal-id-type="publisher-id">Clinical Interventions in Aging</journal-id>
      <journal-title>Clinical Interventions in Aging</journal-title>
      <issn pub-type="ppub">1176-9092</issn>
      <issn pub-type="epub">1178-1998</issn>
      <publisher>
        <publisher-name>Dove Medical Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19503767</article-id>
      <article-id pub-id-type="pmc">2685226</article-id>
      <article-id pub-id-type="publisher-id">cia-4-063</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Karagiannis</surname>
            <given-names>Dimitrios</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cia-4-063">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Georgalas</surname>
            <given-names>Ilias</given-names>
          </name>
          <xref ref-type="aff" rid="af2-cia-4-063">2</xref>
          <xref ref-type="corresp" rid="c1-cia-4-063"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ladas</surname>
            <given-names>Ioannis</given-names>
          </name>
          <xref ref-type="aff" rid="af2-cia-4-063">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eustratios</surname>
            <given-names>Parikakis</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cia-4-063">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mitropoulos</surname>
            <given-names>Panagiotis</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cia-4-063">1</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-cia-4-063"><label>1</label>Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece;</aff>
      <aff id="af2-cia-4-063"><label>2</label>Department of Ophthalmology, &#x201C;G.Genimatas&#x201D; General Hospital, Athens, Greece</aff>
      <author-notes>
        <corresp id="c1-cia-4-063">Correspondence: Ilias Georgalas, Consultant Ophthalmic Surgeon, 59 Chrysanthemon Str., Psychico 15452, Athens, Greece, Tel +30 21 0776 8374, Fax +30 21 0776 8374, Email
<email>igeorgalas@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2009</year>
      </pub-date>
      <!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub-->
      <pub-date pub-type="ppub">
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>5</month>
        <year>2009</year>
      </pub-date>
      <volume>4</volume>
      <issue/>
      <fpage>63</fpage>
      <lpage>65</lpage>
      <copyright-statement>&#xA9; 2009 Karagiannis et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</copyright-statement>
      <copyright-year>2009</copyright-year>
      <abstract>
        <p>A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confirmed absence of intra- or subretinal fluid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.</p>
      </abstract>
      <kwd-group>
        <kwd>idiopathic juxtafoveal retinal telangiectasis</kwd>
        <kwd>ranibizumab</kwd>
        <kwd>subretinal neovascularization</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Gass and Blodi<xref ref-type="bibr" rid="b1-cia-4-063">1</xref> defined bilateral acquired retinal telangiectasis or perifoveal telangiectasia or type 2A telangiectasis as a rare retinal disease characterized by retinal thickening temporal to the fovea, right-angle venules, retinal pigment epithelial (RPE) hyperplastic plaques, and crystalline deposits. Bilateral acquired retinal telangiectasis can be divided into five stages. The disease is usually becoming symptomatic through the sixth decade of life when complicated by subretinal neovascularization which is localized mostly subfoveally in stage 5 of the disease.<xref ref-type="bibr" rid="b1-cia-4-063">1</xref>&#x2013;<xref ref-type="bibr" rid="b3-cia-4-063">3</xref></p>
      <p>We report the outcome of treatment with 0.5 mg intravitreal ranibizumab in a patient with a subretinal neovascular membrane secondary to idiopathic juxtafoveal retinal telangiectasis.</p>
    </sec>
    <sec>
      <title>Case history</title>
      <p>A 65-year-old Caucasian lady presented to our clinic complaining of decreased vision in her left eye (LE). On presentation, best-corrected visual acuity (BCVA) was 10/10 in the right eye (RE) and 1/20 LE. Anterior segment examination was unremarkable in both eyes and intraocular pressures were within normal limits. Fundus biomicroscopy revealed in the right macula, slightly dilated right-angle veins with RPE hyperplasia beneath them (<xref ref-type="fig" rid="f1-cia-4-063">Figure 1A</xref>). In addition to these findings, in the left macula there was subretinal hemorrhage (<xref ref-type="fig" rid="f1-cia-4-063">Figure 1B</xref>). The clinical appearance of the macular area of the LE was consistent with idiopathic juxtafoveal retinal telangiectasis complicated by subretinal neovascularization. Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed and confirmed the above diagnosis (<xref ref-type="fig" rid="f1-cia-4-063">Figures 1C</xref>&#x2013;D, <xref ref-type="fig" rid="f2-cia-4-063">2</xref>, <xref ref-type="fig" rid="f3-cia-4-063">3A</xref>). OCT of the LE revealed the characteristic appearance of outer and inner retina having similar reflectivity and an area temporal to the fovea with high reflectivity corresponding to the temporal area of choroidal neovascularization (CNV) (<xref ref-type="fig" rid="f3-cia-4-063">Figure 3A</xref>), which was observed in the angiogram. After a discussion outlining the possible risks and benefits of the treatment, the patient was started on 0.5 mg intravitreal ranibizumab in the LE. Based on the findings of FA and OCT which were performed monthly, the patient underwent three intravitreal injections of ranibizumab every month for three months. Following these injections, BCVA increased to 3/10 and both clinical and angiographic appearances showed significant improvement with minimal leakage in FA and absence of intra- or subretinal fluid in OCT and significant reduction in retinal thickness; the RPE remained thickened (<xref ref-type="fig" rid="f3-cia-4-063">Figures 3B</xref>, <xref ref-type="fig" rid="f4-cia-4-063">4A</xref>&#x2013;B). Examinations were repeated monthly for another 12 months and showed no recurrence of CNV.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Bilateral acquired retinal telangiectasis or retinal telangiectasis type 2A, according to Gass and Blodi, or type 2 perifoveal telangiectasia according to the classification by Yannuzzi is a symmetrical disease.<xref ref-type="bibr" rid="b1-cia-4-063">1</xref>,<xref ref-type="bibr" rid="b3-cia-4-063">3</xref> The area involved is usually less than a disc diameter and is typically temporal to the fovea.<xref ref-type="bibr" rid="b1-cia-4-063">1</xref> Gas and Blodi divided the development of group 2A telangiectasis into five stages.<xref ref-type="bibr" rid="b1-cia-4-063">1</xref> Stage 1 is found on FA on the asymptomatic fellow eye as staining at the level of the RPE. Stage 2 is characterized by the loss of transparency of the retina near the fovea and visible telangiectasis only in FA. In stage 3, FA shows capillary dilatation and staining. Stage 4 reveals migrating RPE cells appearing as stellate foci along the right-angle venules. Stage 5, according to Gass and Blodi, or the proliferative stage according to Yannuzzi&#x2019;s classification of the disease, is associated with subretinal neovascularization.<xref ref-type="bibr" rid="b1-cia-4-063">1</xref>,<xref ref-type="bibr" rid="b3-cia-4-063">3</xref></p>
      <p>According to Engelbrecht and colleagues<xref ref-type="bibr" rid="b2-cia-4-063">2</xref> the natural course of the disease in stage 5 is not good in 80% of cases, resulting to visual acuity of 1/20 or less.</p>
      <p>Snyers and colleagues showed that from four patients treated with photodynamic therapy (PDT), three of those retained their visual acuity, however, there was no significant improvement.<xref ref-type="bibr" rid="b4-cia-4-063">4</xref></p>
      <p>Vascular endothelial growth factor (VEGF) is a major key player for angiogenesis in the eye in several physiologic and pathologic conditions. Concerning anti-VEGF therapy in ocular disease, clinical trials with ranibizumab show a beneficial effect for all subtypes of CNV including diseases such as pathological myopia and age-related macular degeneration. In addition, anti-VEGF therapy showed beneficial results, both clinically and anatomically, for idiopathic macular telangiectasia which was not associated with subretinal neovascularization.<xref ref-type="bibr" rid="b5-cia-4-063">5</xref></p>
      <p>Recently, Ruys and colleagues have reported that the intravitreal delivery of bevacizumab (Avastin), with or without PDT was beneficial for both anatomical and visual outcome for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis.<xref ref-type="bibr" rid="b6-cia-4-063">6</xref> Other reports also support this beneficial outcome of bevacizumab (Avastin) (<xref ref-type="table" rid="t1-cia-4-063">Table 1</xref>).<xref ref-type="bibr" rid="b7-cia-4-063">7</xref>&#x2013;<xref ref-type="bibr" rid="b9-cia-4-063">9</xref> In most of these cases the neovascularization ceased after two injections of bevacizumab.<xref ref-type="bibr" rid="b7-cia-4-063">7</xref></p>
      <p>Also, combined PDT and intravitreal ranibizumab appears to be efficacious in the treatment of subretinal neovascularization associated with proliferative type 2 idiopathic macular telangiectasia (<xref ref-type="table" rid="t1-cia-4-063">Table 1</xref>).<xref ref-type="bibr" rid="b10-cia-4-063">10</xref></p>
      <p>In our case we chose to use ranibizumab since it has been designed for intraocular use; three intravitreal applications of ranibizumab, repeated monthly, alone without any additional session of PDT, were sufficient to cease the neovascularization during a follow-up time of 12 months.</p>
      <p>In conclusion, intravitreal ranibizumab seems to have favorable results in the treatment of subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. Further studies are required to evaluate the above findings, although the implementation of large-series studies remains a challenge due to the rarity of cases with subretinal neovascularization secondary to idiopathic juxtafoveal retinal telangiectasis.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Disclosure</bold>
        </p>
        <p>The authors report no conflicts of interest in this work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-cia-4-063">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gass</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Blodi</surname>
              <given-names>BA</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic juxtafoveal retinal telangiectasis. Update of classification and follow-up study</article-title>
          <source>Ophthalmology</source>
          <year>1993</year>
          <volume>100</volume>
          <fpage>1536</fpage>
          <lpage>1546</lpage>
          <pub-id pub-id-type="pmid">8414413</pub-id>
        </citation>
      </ref>
      <ref id="b2-cia-4-063">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engelbrecht</surname>
              <given-names>NE</given-names>
            </name>
            <name>
              <surname>Aaberg</surname>
              <given-names>TM</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Sung</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis</article-title>
          <source>Arch Ophthalmol</source>
          <year>2002</year>
          <volume>120</volume>
          <fpage>320</fpage>
          <lpage>324</lpage>
          <pub-id pub-id-type="pmid">11879135</pub-id>
        </citation>
      </ref>
      <ref id="b3-cia-4-063">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yannuzzi</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Bardal</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Freund</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Eandi</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Blodi</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>idiopathic macular telangiectasia</article-title>
          <source>Arch Ophthalmol</source>
          <year>2006</year>
          <volume>124</volume>
          <fpage>450</fpage>
          <lpage>460</lpage>
          <pub-id pub-id-type="pmid">16606869</pub-id>
        </citation>
      </ref>
      <ref id="b4-cia-4-063">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Snyers</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Verougstraete</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Postelmans</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Leys</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hykin</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis</article-title>
          <source>Am J Ophthalmol</source>
          <year>2004</year>
          <volume>137</volume>
          <fpage>812</fpage>
          <lpage>819</lpage>
          <pub-id pub-id-type="pmid">15126144</pub-id>
        </citation>
      </ref>
      <ref id="b5-cia-4-063">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Charbel Issa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Finger</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Holz</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Scholl</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Eighteen-month follow-up of intravitreal bevacizumab in type 2idiopathic macular telangiectasia</article-title>
          <source>Br J Ophthalmol</source>
          <year>2008</year>
          <volume>92</volume>
          <fpage>941</fpage>
          <lpage>945</lpage>
          <pub-id pub-id-type="pmid">18577646</pub-id>
        </citation>
      </ref>
      <ref id="b6-cia-4-063">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruys</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>De Laey</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Vanderhaeghen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Van Aken</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane</article-title>
          <source>Eye</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1433</fpage>
          <lpage>1434</lpage>
          <pub-id pub-id-type="pmid">17693997</pub-id>
        </citation>
      </ref>
      <ref id="b7-cia-4-063">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mandal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Venkatesh</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Vohra</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Garg</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2007</year>
          <volume>245</volume>
          <fpage>1825</fpage>
          <lpage>1829</lpage>
          <pub-id pub-id-type="pmid">17345090</pub-id>
        </citation>
      </ref>
      <ref id="b8-cia-4-063">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jorge</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Calucci</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>IU</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2007</year>
          <volume>245</volume>
          <fpage>1045</fpage>
          <lpage>1048</lpage>
          <pub-id pub-id-type="pmid">17136357</pub-id>
        </citation>
      </ref>
      <ref id="b9-cia-4-063">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moon</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Berger</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Tolentino</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Misch</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telaniectasis</article-title>
          <source>Ophthalmic Surg Lasers Imaging</source>
          <year>2007</year>
          <volume>38</volume>
          <fpage>164</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">17396701</pub-id>
        </citation>
      </ref>
      <ref id="b10-cia-4-063">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rishi</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Shroff</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rishi</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane associated with type 2 idiopathic macular telangiectasia</article-title>
          <source>Graefes Arch Clin Exp Ophthalmol</source>
          <year>2008</year>
          <volume>246</volume>
          <fpage>619</fpage>
          <lpage>621</lpage>
          <pub-id pub-id-type="pmid">18193448</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <fig id="f1-cia-4-063" position="float">
      <label>Figure 1</label>
      <caption>
        <p><bold>A</bold>) Right eye: Color fundus picture showing slightly dilated right-angle veins with retinal pigment epithelium hyperplasia beneath them. <bold>B</bold>) Left eye: Color fundus picture showing subretinal hemorrhage inferior and temporal to the fovea. <bold>C</bold>) Venous phase of FA of the LE depicts early hyperfluorescence corresponding to the neovascular membrane and hypofluorescence inferior to the membrane corresponding to the subretinal hemorrhage. <bold>D</bold>) Late phase of FA showing leakage from the neovascular membrane.</p>
        <p><bold>Abbreviations:</bold> FA, fluorescein angiography; LE, left eye; OCT, optical coherence tomography.</p>
      </caption>
      <graphic xlink:href="cia-4-063f1"/>
    </fig>
    <fig id="f2-cia-4-063" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Oblique section of OCT of the LE.</p>
        <p><bold>Abbreviations:</bold> LE, left eye; OCT, optical coherence tomography.</p>
      </caption>
      <graphic xlink:href="cia-4-063f2"/>
    </fig>
    <fig id="f3-cia-4-063" position="float">
      <label>Figure 3</label>
      <caption>
        <p><bold>A</bold>) Oblique section of OCT of the LE revealing the characteristic appearance of outer and inner retina having similar reflectivity and an area temporal to the fovea with high reflectivity corresponding to the temporal area of choroidal neovascularization observed in the angiogram. <bold>B</bold>) OCT of the same section of LE revealing significant reduction in retinal thickness. The RPE remains thickened.</p>
        <p><bold>Abbreviations:</bold> LE, left eye; OCT, optical coherence tomography; RPE, retinal pigment epithelium.</p>
      </caption>
      <graphic xlink:href="cia-4-063f3"/>
    </fig>
    <fig id="f4-cia-4-063" position="float">
      <label>Figure 4</label>
      <caption>
        <p><bold>A</bold>) Left eye: Color fundus picture following ranibizumab treatment revealing significant improvement with no subretinal hemorrhage. <bold>B</bold>) late venous phase of FA of the LE showing minimal leakage due to telangiectasis but no signs of active neovascular membrane.</p>
        <p><bold>Abbreviations:</bold> FA, fluorescein angiography; LE, left eye.</p>
      </caption>
      <graphic xlink:href="cia-4-063f4"/>
    </fig>
    <table-wrap id="t1-cia-4-063" position="float">
      <label>Table 1</label>
      <caption>
        <p>Anti-VEGF for the treatment of subretinal neovascular membrane associated with type 2 idiopathic macular telangiectasia: Summarized review of the literature</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Author publication</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Patients</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Anti-VEGF</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>PDT</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Follow-up (months)</bold>
            </th>
            <th align="left" valign="top" rowspan="1" colspan="1">
              <bold>Year of publication</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Rishi et al<xref ref-type="bibr" rid="b10-cia-4-063">10</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ranibizumab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Yes</td>
            <td align="left" valign="top" rowspan="1" colspan="1">16</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2008</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Mandal et al<xref ref-type="bibr" rid="b7-cia-4-063">7</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Bevacizumab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">No</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3&#x2013;6</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2008</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Jorge et al<xref ref-type="bibr" rid="b8-cia-4-063">8</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Bevacizumab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">No</td>
            <td align="left" valign="top" rowspan="1" colspan="1">24</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2008</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Ruys et al<xref ref-type="bibr" rid="b6-cia-4-063">6</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">2</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Bevacizumab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Case 1: Yes Case 2: No</td>
            <td align="left" valign="top" rowspan="1" colspan="1">1&#x2013;3</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2007</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Moon et al<xref ref-type="bibr" rid="b9-cia-4-063">9</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">1</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Bevacizumab</td>
            <td align="left" valign="top" rowspan="1" colspan="1">No</td>
            <td align="left" valign="top" rowspan="1" colspan="1">3</td>
            <td align="left" valign="top" rowspan="1" colspan="1">2007</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn1-cia-4-063">
          <p><bold>Abbreviations:</bold> PDT, photodynamic therapy; VEGF, vascular endothelial growth factor.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-wrap>
</article>
</pmc-articleset>
